Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220250023COLLOIDAL BREWING SYSTEM
US 11.08.2022
Int.Class B01J 13/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
13Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
Appl.No 17665888 Applicant GAILE MATTISON Inventor GAILE MATTISON

A colloidal brewing system has a transparent container assembly with a watertight bottom portion and an open top portion, the container assembly adapted to contain water. A removable lid electronic housing with two replaceable electrically charged silver rod members is disposed on a bottom portion of the lid member, the rod members extending substantially to near the bottom of the container assembly. A magnetic stir assembly substantially centers an interior bottom portion of the container assembly and to rotate, in the water, on a parallel plane to the bottom portion. A receiver and transmitter coil assembly are disposed within a base container assembly, the base container assembly designed to gravitationally support the watertight bottom portion of the transparent container assembly, the receiver coil and transmitter coil assembly inductively coupled to the magnetic stir assembly. The inventive concept has a rechargeable battery, a control panel, power port members, and handle member.

2.20220249518USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTION
US 11.08.2022
Int.Class A61K 31/58
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
58containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin
Appl.No 17725331 Applicant The U.S.A., as represented by the Secretary, Department of Health and Human Services Inventor Peter L. Collins

Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.

3.20220249398Cannabinoid Formulation Containing Active Ingredients and Carrier for Transdermal Absorption to Treat Neuropathy
US 11.08.2022
Int.Class A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
Appl.No 17704318 Applicant William Seidel Inventor William Seidel

The invention relates to a topical formulation in order to deliver an effective amount of broad-spectrum cannabidiol ointment, in conjunction with active ingredients, menthol and camphor. This invention is for the treatment of symptoms and improvement of sensation associated with peripheral neuropathy, particularly of the feet and hands. The present invention also provides for various topical application formulations.

4.20220249519COMPOSITIONS OF HYDROXY ACIDS WITH SALICYLIC ACID AND USES THEREFORE
US 11.08.2022
Int.Class A61K 31/616
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
60Salicylic acid; Derivatives thereof
612having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
616by carboxylic acids, e.g. acetylsalicylic acid
Appl.No 17666964 Applicant Able Derm LLC Inventor Frank DREHER

The present disclosure generally relates to topical compositions comprising a combination of at least one alpha-hydroxy acid (e.g., glycolic acid) combined with at least one beta-hydroxy acid (e.g., salicylic acid) in the presence of water-soluble polystyrenes or appropriate salts thereof. The present disclosure further provides methods of making and using such compositions.

5.20220249557Vaccine and Uses thereof in Cell Therapy
US 11.08.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No 17592601 Applicant Innovative Cellular Therapeutics Holdings, Ltd. Inventor Yang Li

The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ.

6.20220249575FORMULATION AND TREATMENT FOR OPHTHALMIC DISORDERS
US 11.08.2022
Int.Class A61K 35/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
51Umbilical cord; Umbilical cord blood; Umbilical stem cells
Appl.No 17394628 Applicant AVAV LABS LLC Inventor Philipp R. VITTI

The disclosure provides therapeutic ophthalmic formulations, kits, and uses thereof in the treatment of eye pathologies.

7.202022103409Formulierung eines Nanotechnologie-basierten Liefersystems von Nano-Trägern zu Zellen des Immunsystems
DE 11.08.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No 202022103409 Applicant Autade Kalyani Inventor

Eine Formulierung, die auf Nanotechnologie-Abgabe von Nanoträgern an Zellen des Immunsystems basiert, umfassend: eine erste Nano-Träger-Liganden-Zusammensetzung, die aus einem Kohlenhydrat und ähnlichen Resten besteht, die in der Lage sind, eine angeborene Immunantwort für ein Zellsystem zu stimulieren; einen zweiten Nano-Carrier-Liganden, der aus einem T-Zellen-Helferpeptid besteht; einen dritten Nano-Trägerliganden, der ein Gefahrensignal umfasst, das aus Endotoxinen, Hitzeschockproteinen, Nukleotiden, reaktiven Sauerstoffzwischenprodukten, Abbauprodukten der extrazellulären Matrix besteht; und wobei die Nano-Träger-Liganden-Zusammensetzung kovalent an den Kern gebunden ist, wobei die Nano-Träger-Liganden-Zusammensetzung eine Kohlenhydrateinheit umfasst.

8.WO/2022/165698CLAY BASED MASK FOR CARING FOR KERATIN MATERIALS
WO 11.08.2022
Int.Class A61K 8/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
Appl.No PCT/CN2021/075222 Applicant L'OREAL Inventor MA, Yuan
Disclosed is a mask for caring for keratin materials, comprising: A) a water insoluble substrate having a porosity ranging from 0.2% to 0.6% and a density ranging from 0.01 g/cm 3 to 0.2 g/cm 3; B) a composition in the form of an oil-in-water emulsion impregnated into the substrate comprising: i) at least 2 wt.% of magnesium aluminum silicate, relative to the total weight of the composition; ii) at least one clay different from magnesium aluminum silicate; iii) at least one hydrophilic thickener; iv) at least one non-ionic surfactant; and v) at least one emollient; wherein the composition has a viscosity ranging from 40 UD to 80 UD. It also relates to a non-therapeutic process for caring for keratin materials, comprising: (i) applying the mask on the keratin materials; (ii) allowing the mask to remain on the keratin materials for a period of time; and (iii) removing the mask from the keratin materials.
9.WO/2022/166283CARBOHYDRATE COMPOSITION AS PHARMACEUTICAL COMPOSITION, AND USE THEREOF
WO 11.08.2022
Int.Class A61K 31/715
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Appl.No PCT/CN2021/128375 Applicant MEDGAEA JAPAN CO., LTD. Inventor WU, Chang-Jer
The present invention provides a carbohydrate composition as a pharmaceutical composition, and use thereof. The carbohydrate composition comprises fucose, glucuronic acid, galactose, and arabinose. Based on the total weight of the carbohydrate composition, the content of the fucose is 45.5 wt% to 76 wt%, the content of the glucuronic acid is 11 wt% to 19 wt%, the content of the galactose is 4.5 wt% to 14.5 wt%, and the content of the arabinose is 5.5 wt% to 18 wt%. A pharmaceutical composition comprising the carbohydrate composition is provided. The carbohydrate composition and the pharmaceutical composition provided by the present invention can achieve the effects of taking care of the skin, inhibiting skin allergy, inhibiting skin inflammation, or alleviating atopic dermatitis.
10.WO/2022/166913MODIFIED RED BLOOD CELLS AND USES THEREOF FOR TREATING HYPERURICEMIA AND GOUT
WO 11.08.2022
Int.Class C12N 5/078
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
Appl.No PCT/CN2022/075140 Applicant WESTLAKE THERAPEUTICS (HANGZHOU) CO. LIMITED Inventor GAO, Xiaofei
Provided are a red blood cell (RBC) having an agent linked thereto, wherein the agent is linked to at least one endogenous, non-engineered membrane protein of the RBC by by a sortase-mediated glycine conjugation or lysine side chain e-amino group conjugation, and wherein the agent comprises a uric acid degrading polypeptide, a uric acid transporter or the combination; a method for preparing the RBC; and the use of the RBC for preventing or treating a disorder, condition or disease associated with an elevated uric acid level including hyperuricemia or gout.